#cantor-fitzgerald
Latest news and interesting information about cantor-fitzgerald.
Cantor Fitzgerald raises Dycom price target to $654
Cantor Fitzgerald raises Dycom price target to $654, citing FTTH growth and strong Q1 results. Stock up 134% in a year.
Okta price target raised to $110 by Cantor
Cantor Fitzgerald raised Okta price target to $110 from $100, citing workforce growth. Stock has 17% upside. Earnings due May 28.
Cantor Fitzgerald Reiterates Workday Rating on AI Growth
Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.
Cantor Reiterates Overweight on ORIC Stock
Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.
Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.
Cantor Fitzgerald Reaffirms Nvidia Overweight Rating
Cantor Fitzgerald reaffirms Nvidia Overweight rating, $350 target. Strong data center growth drives performance.
Cantor Fitzgerald raises PANW price target to $285
Cantor Fitzgerald raises Palo Alto Networks price target to $285, citing platformization, AI tailwinds, and strong partner results.
Cantor Fitzgerald Initiates X-Energy with Overweight
Cantor Fitzgerald starts X-Energy with Overweight rating and $38 target, citing strategic position in advanced nuclear.
...